Warning Letter — Ready Med
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Ready Med following an inspection of their operations. The letter identifies specific regulatory violations regarding the firm's compliance with established standards.
This action specifically affects Ready Med and its internal departments responsible for manufacturing, quality control, and regulatory compliance.
The issuance of a Warning Letter by CDER signifies that the agency has identified significant violations that require formal corrective actions. Failure to address these concerns could lead to further enforcement actions, such as seizure or injunction. Regulatory teams should interpret this as a signal of heightened agency scrutiny regarding the firm's production or quality management systems.
Quality and regulatory leadership should conduct an immediate gap analysis of current manufacturing documentation and facility standards against established requirements. Preparation for follow-up inspections or a formal response to the agency is necessary to address the specific citations mentioned in the letter.
FDA Warning Letter issued to: Ready Med. 06/08/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ready-med-730317-06082026
Open in openFDA / FDA.gov